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Prostasin protein has been found to be a useful marker for
determination of the invasiveness of and as a means to treat
human carcinomas. Using RT-PCR and western blot
analyses, prostasin protein and mRNA expression were
found in normal human prostate epithelial cells and the
human prostate cancer cell line LNCaP, but not in the highly
invasive human prostate cancer cell lines DU-145 and PC-3.
Imunohistochemistry studies of human prostate cancer
specimens revealed a down-regulation of prostasin in highgrade tumors. Using RT-PCR and western blot analyses,
prostasin protein and mRNA expression were found in a
non-invasive human breast cancer cell line, MCF-7, while
invasive human breast cancer cell lines MDA-MB-231 and
MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast
cancer cell line, MDA-MB-453, was shown to express
prostasin mRNA but not prostasin protein. Transfection of
DU-145 and PC-3 cells with a full-length human prostasin
cDNArestored prostasin expression and reduced the in vitro
invasiveness by 68% and 42%, respectively. Transfection of
MDA-MB-231 and MDA-MB-435s cells with a full-length
human prostasin cDNA restored prostasin expression and
reduced the in vitro invasiveness by 50% for either cell line.
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advanced hormone-resistant prostate cancer. [Review] [ 63
refs] Cancer. 71(3 Suppl): 1098-109, 1993 and Petrylak,
TREATING INVASIVE CARCINOMAS
1993). Of the remaining 50% cases, 1/3 (-50,000) are
diagnosed as organ-confined but micrometastasis may be
This invention relates to prostasin and its use in the
diagnosis and treatment of prostate and breast cancers, and 5 present. The final group of patients (-100,000) have truly
organ-confined prostate cancer and can be cured by radical
claims the priority to U.S. Provisional Application Serial
prostatectomy (Sgrignoli AR Walsh P C. Steinberg G D.
No. 60/174,801 filed Jan. 6, 2000 and was supported in part
Steiner M S. Epstein J I. Prognostic factors in men with
by Department of Defense Prostate Cancer Research Grant
stage D 1 prostate cancer: identification of patients less
DAMD17-98-l-8590, and in part by grants to principal
likely to have prolonged survival after radical prostatectomy
10
investigator K. X. CHAI from the Florida Hospital Gala
[see comments]. Journal of Urology. 152(4):1077-81, 1994;
Endowed Program for Oncologic Research.
Zincke H. Oesterling J E. Blute ML. Bergstralh E J. Myers
BACKGROUND AND PRIOR ART
R P. Barrett D M. long term (15 years) results after radical
prostatectomy for clinically localized (stageT2c or lower)
For men in the U.S., prostate cancer is the most commonly diagnosed cancer, and the second leading cause of 15 prostate cancer [see comments]. Journal of Urology. 152(5
Pt 2): 1850-7, 1994) or left untreated (watchful waiting)
cancer-related death (Greenlee R. T., Murray T. Bolden S,
without the risk of life-threatening or life-altering. For the
Wingo Pa. Cancer statistics, 1999. Ca: a Cancer Journal for
patients with non-organ-confined prostate cancers
Clinicians 2000;50:7-33). Prostate cancers originate as
(discovered via either biopsy or surgery), undergoing syslocalized lesions; some of these localized lesions will
progress to become invasive, migratory and metastatic. Our 20 temic treatment early is essential to the management of their
cancer (Yagoda A Petrylak D. Cytotixic chemotherapy for
current understanding of the mechanisms of the prostate
advanced hormone-resistant prostate cancer [Review] [ 63
cancer invasion process, however, is poor. Our ability to
refs] Cancer. 71(3 Suppl): 1098-109, 1993). Consequently,
predict the acquisition of invasive potentials by a prostate
it will be ideal, both medically and economically, if one
cancer is limited.
The mechanisms leading to the development of a prostate 25 could precisely predict upon early pathological examination
of the tumor, which group of patients will have truly
cancer are complex. Currently, it is believed to be the result
organ-confined disease versus which group will have invaof multiple transformation steps from normal prostate glansive prostate cancer.
dular cells (Carter H. B. Piantadosi S. Isaacs J. T. Clinical
Clinical staging of prostate cancer generally depends on
evidence for and implications of the multistep development
of prostate cancer. Journal of Urology. 143(4):742-6, 1990). 30 the results of three tests that are performed in the following
order: a PSA (prostate-specific antigen) blood test as a
The initial steps result in what are described as prostatic
screening method; DRE (digital rectal examination) for an
interepithelial neoplastic (PIN) lesions (Isaacs J. T. Molecuinitial indication of palpable disease; and, a biopsy to obtain
lar markers for prostate cancer metastasis. Developing diagsamples for histological examination. Prostate cancers,
nostic methods for predicting the aggressiveness of prostate
cancer. [Review] [92 refs] American Journal of Pathology. 35 removed either via biopsy or surgery, are graded histologically by the system of Gleason. (Gleason D F. Classification
150(5):1511-21, 1997). These PIN lesions may then typiof prostatic carcinomas. Cancer Chemotherapy Reportscally have three different fates based on an assessment of
Partl. 50(3):125-8, 1966), which is an evaluation of how
their impact to the patient. The PIN lesions can remain as
aggressive and how poorly-differentiated the prostate cansuch, not producing histologically detectable prostate
cancer, or further transform into histologically detectable 40 cers are. The aggressiveness of prostate tumors: of low
Gleason scores ( <5) is limited; of high Gleason scores
prostate cancer. Most of the histologically detectable pros(8-10) are highly aggressive; but, for the intermediate
tate cancers will be asymptomatic in the patient and remain
Gleason-score (5-7) prostate cancers (76% of prostate
non-manifest clinically as many are discovered post-mortem
tumors), the accuracy of predicting their aggressiveness is
(Carter H Coffey D. Prostate Cancer: the magnitude of the
problem in the United States. In a Multidisciplinary Analysis 45 poor (Gleason D F. Mellinger GT. Prediction of prognosis
for prostatic adenocarcinoma by combined histological
of Controversies in the Management of Prostate Cancer.
grading and clinical staging. Journal of Urology. 111
(Eds. Coffey D. Resnick M. Door R. et al.), ppl-9, Plenum
(1):58-64, 1974). Thus, the ability to accurately determine
Press, 1988; Carter H B Piantadosi S. Issacs J. T. Clinical
the aggressiveness of these intermediate Gleason-score
evidence for implications of the multistep development of
prostate cancer. Journal of Urology. 143(4):742-6,1990; 50 prostate tumors has remained as a practical challenge to, and
a primary goal for, prostate cancer research (Isaacs J T.
Scardino P T. Weaver R. Hudson M A Early detection of
Molecular markers for prostate cancer metastasis. Developprostate cancer. [Review] [102 refs] Human Pathology.
ing diagnostic methods for predicting the aggressiveness of
23(3):211-22, 1999). Prostate cancers are diagnosed cliniprostate cancer. [Review] [92 refs] American Journal of
cally by an estimate of size and location using the TNM
staging system (Denis L J. Staging and prognosis of prostate 55 Pathology. 150(5): 1511-21, 1997). Especially with regard to
the number of patients (150,000) facing a decision of
cancer. European Urology. 24 Suppl 2:13-8, 1993), and by
whether to undergo systemic treatment, the most urgent
pathological staging based on an examination of the histoldemand in prostate cancer care is the development of
ogy of the removed prostate via either biopsy or prostatecmethods to enhance our ability to accurately predict the
tomy using a system by D. F. Gleason, (Gleason D F.
Classification of prostatic carcinomas. Cancer Chemo- 60 aggressiveness of the tumors with Gleason scores of 5-7.
therapy Reports-Part 1. 50(3):125-8, 1966). About 50% of
It is now commonly believed that cancers occur via
prostate cancer cases receiving treatment are diagnosed
multiple transformation steps by accumulating mutations in
clinically as advanced, or, non-organ-confined (Scardino P
three classes of genes: proto-oncogenes (Park M. OncoT. Weaver R. Hudson M A Early detection of prostate
genes. In The Genetic Basis of Human Cancer (Eds. Vogelcancer. [Review] [102 refs] Human Pathology. 23(3): 65 stein Band Kinzler KW), pp205-28, McGraw-Hill Health
211-22, 1992), for which no effective treatment exists
Professions Divisions, 1998); tumor-suppressor genes
(Knuutila S. Aalto Y. Bjorkqvist AM. EL-Rifai W. Hemmer
(Yagoda A Petrylak D. Cytotoxic chemotherapy for
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S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S. Larramendy M
prognosis in patients with prostate cancer. Cancer Research.
L. Lushnikova T. Manni 0. Pere H. Tapper J. Tarkkanen M.
54(14):3929-33, 1994); ~ic integrin (Fornaro M. Tallini G.
Varis A Wasenius V M. Wolf M. Zhu Y. DNA copy number
Bofetiado CJ. Bosari S. Languino LR. Down-regulation of
losses in human neoplasms. [Review] [197 refs] American
~lC integrin, an inhibitor of cell proliferation, in prostate
Journal of Pathology. 155(3):683-94, 1999); and, DNA 5 carcinoma. American Journal of Pathology. 149(3):765-73,
repair genes (Knuutila S. Aslto Y. Bjorkqvit AM. EL-Rifai
1996 Fornaro M. Manzotti M. Tallini G. Slear A E. Bosari
W. Hemmer S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S.
S. Ruoslahti E. Languino LR. ~lC integrin in epithelial cells
Larramedy ML. Lushnikova T. Manni 0. Pere H. Tapper J.
correlates with a nonproliferative phenotype: forced expresTarkkanen M. VarisA. Wasenius V M. Wolf M. Zhu Y. DNA
sion of ~lC inhibits prostate epithelial cell proliferation.
copy number losses in human neoplasms. [Review] [197 10 American Journal of Pathology. 153(4):1079-87, 1998; p27
refs] American Journal of Pathology. 155(3):683-94, 1999).
(kipl) (Tsihlias J. Kapusta LR. DeBoer G. Morava-Protzner
The histological prostate cancers for which the prediction of
I. Zbieranowski I. Bhattacharya N. Catzavelos G C. Klotz L
clinical aggressiveness is difficult (those with the intermeH. Slingerland JM. Loss of cyclin-dependent kinase inhibidiate Gleason scores 5-7) probably have not gone through
tor p27Kipl is a novel prognostic factor in localized human
the necessary "multi-step" transformation to acquire the 15 prostate adenocarcinoma. Cancer Research. 58(3):542-8,
potentials to behave aggressively (as would the high-grade
1998); and CD44 (Lou W. Krill D. Dhir R. Becich M J. Dong
cancers). This notion was supported by studies comparing
J T. Frierson H F Jr. Isaacs W B. Isaacs J T. Gao A C.
the course of prostate cancer development among men in
Methylation of the CD44 metastasis suppressor gene in
Japan and in the U.S., and Japanese men who migrated to the
human prostate cancer. Cancer Research. 59(10):2329-31,
U.S. (Carter H B. Piantadosi S. Isaacs J T. Clinical evidence 20 1999). By using the method of immunohistochemistry, these
for and implications of the multistep development of prosgenes were found to be down-regulated in prostate cancer.
tate cancer. Journal of Urology, 1990; Haenszel W. Kurihara
KAI's down regulation is a potential predictor of metastasis
M. Studies of Japanese Migrants. I. Mortality form cancer
(Dong, et al., 1996: Ueda et al., 1996). While E-cadherin's
and other diseases among Japanese in the United States.
down regulation is strongly correlated to higher Gleason
Journal of the National Cancer Institute.40(1):43-68, 1968; 25 grades. Functional studies of these genes have given clues to
Akazaki K. Stemmerman G N. Comparartive study of latent
their role in prostate cancer or normal prostate biology.
carcinoma of the prostate among Japanese in Japan and
(Debruyne F M. Isaacs W B. Expression of the cellular
Hawaii. Journal of the National Cancer Institute. 50(5):
adhesion molecule E-cadherin is reduced or absent in high1137-44, 1973; Dunn J E. Cancer epidemiology in populagrade prostate cancer. Cancer Research. 52(18):5104--9,
tions of the United States-with emphasis on Hawaii and 30 1992; Umbas R. Isaacs W B. Bringuier PP. Schaafsma HE.
California-and Japan. Cancer Research. 35(11 Pt.2):
Karthaus H F. Oosterhof G 0 Debruyne F M. Schalken J A
3240-5, 1975). The findings were that first- and secondDecreased E-cadherin expression is associated with poor
generation Japanese men who migrated to the U.S. have a
prognosis in patients with prostate cancer. Cancer Research.
higher prostate cancer incident rate than native Japanese
54(14):3929-33, 1994; metastasis suppressor gene during
men. The emigrant Japanese men's prostate cancer incident 35 the progression of human prostatic cancer infrequently
rate is similar to that of men in the U.S. Investigating the
involves gene mutation or allelic loss. Cancer Research.
changes of expression in these three classes of cancer56(19):4387-90; 1996 Ueda T. Ichikawa T. Tamaru J.
relevant genes during the course of prostate cancer develMikata A Akakura K. Akimoto S. Imai T. Yoshie 0.
opment will lead to a better understanding of the processes
Shiraishi T. Yatani R. Ito H. Shimazaki J. Expression of the
by which prostate cancers acquire their aggressive paten- 40 KAil protein in benign prostatic hyperplasia and prostate
tials. The discovery of molecules whose changes can be
cancer. American Journal of Pathology. 149(5):1435-40,
correlated to the staging of prostate cancer will provide new
1996) while E-cadherin's down-regulation is strongly cortools to improve our ability to better predict the aggressive
related to higher Gleason grades (Umbas R. Schalken J A
behaviors of prostate cancer. This approach is now comAalders T W. Carter B S. Karthaus H F. Schaafsma H E.
monly referred to as "molecular staging".
45 Debruyne F M. Isaacs W B. Expression of the cellular
adhesion molecule E-cadherin is reduced or absent in highDown-regulated genes such as tumor suppressors, invasion suppressors or metastasis suppressors may be used as
grade prostate cancer. Cancer Research. 52(18):5104--9,
prostate cancer markers. Examples of these genes that can
1992; Umbas R. Isaacs W B. Bringuier PP. Schaafsma HE.
potentially serve as prostate cancer markers for "molecular
Karthaus HF. Oosterhof G 0. Debruyne FM. Schalken J A
staging" are: KAil (Dong J T. Suzuki H. Pin S S. Bova G 50 Decreased E-cadherin expression is associated with poor
S., Schalken J A, Issacs W B, Barrett J C. Issace I T.
prognosis in patients with prostate cancer. Cancer Research.
54(14):3929-33, 1994) Functional studies of these genes
Down-regulation of the KAil metastasis suppressor gene
during the progression of human prostatic cancer infrehave given clues to their role in prostate cancer or normal
quently involves gene mutation or allelic loss. Cancer
prostate biology. Human KAI suppress metastasis of rat
Research. 56(19): 4387-90, 1996); (Ueda T, Ichikawa T., 55 prostate cancer cells upon gene transfer (Dong JT. Lamb P
W. Rinker-Schaeffer C W. Vukanovic J. Ichikawa T. Isaacs
Tamaru j, Mikata A, Akakura K, Akimoto S, Imai T. Yoshie
0. Shiraishi T. Yatani R. Ito H. Shimazaki J., Expression fof
J T. Barrett J C. KAil, a metastasis suppressor gene for
the KAll protein in benign prostatic hyperplasia and prosprostate cancer on human chromosome llpll.2 [see
tate cancer. American Journal of Pathology 149(5):
comments]. Science. 268(5212):884-6, 1995). ~ic and p27
1435-40, 1996); E-cadherin (Umbas R. Isaacs W B Brin- 60 (kip 1 ) are involved in signaling pathway that inhibits cell
proliferation (Fornaro M. Tallini G. Zheng D Q. Flanagan W
guier PP. Schaafsma H E. Karthaus H F. Oosterhof G 0.
Debruyne FM. Schalken J A Decreased E-Cadherin expresM. Manzotti M. Languino LR. p27(kipl) acts as a downsion is associated with poor prognosis is patients with
stream effector of and is coexpressed with the betalC
prostate cancer. Cancer Research. 52(18):5104-9, 1992,
integrin in prostatic adenocarcinoma. Journal of Clinical
Umbas R. Isaacs W B. Bringuier P P. Schaafsma H E. 65 Investigation. 103(3):321-9, 1999). E-cadherin expression
is progressively lost during the transformation of rat prostate
Karthaus H F. Oosterhof G 0 Debruyne F M. Schalken J A
Decreased E-cadherin expression is associated with poor
cancer from non-invasive to invasive (Bussemakers M J.
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van Moorselaar R J. Giroldi LA Ichikawa T. Isaacs J T.
statistics, 1999. Ca: a Cancer Journal for Clinicians
Takeichi M. Debruyne F M. Schalken J A Decreased
2000;50:7-33). Breast ductal carcinoma in situ (hereinafter
expression of E-cadherin in the progression of rat prostatic
indicated as DCIS) incidence has increased dramatically
cancer. Cancer Research. 52(10):2916-22, 1992), and it has
since 1983 as a result of implementing screening programs
also been shown to be an invasion suppressor (Lou W. Krill 5 (Ernster V L. Barclay J. Increases in ductal carcinoma in situ
D. Dhir R. Becich M J. Dong J T. Frierson HF Jr. Isaacs W
(DCIS) of the breast in relation to mammography: a
B. Isaacs J T. Gao AC. Methylation of the CD44 metastasis
dilemma. [Review] [34 refs] Journal of the National Cancer
suppressor gene in human prostate cancer. Cancer Research.
Institute. Monographs. (22): 151-6, 1997). DCIS is
59(10):2329-31, 1999). CD44 loss of expression is associdescribed as a malignant growth of epithelial cells within the
ated with high metastatic ability and transfection of CD44 10 ducts and lobules of the breast, and is believed to be the
suppresses metastasis without affecting tumorigenecity of
precursor of all invasive breast carcinoma. DCIS itself is
rat prostate cancer cells (Gao AC. Lou W. Dong J T. Isaacs
non-life-threatening; however, current treatment options for
J T. CD44 is a metastasis suppressor gene for prostatic
DCIS include masectomy, lumpectomy, radiotherapy or
cancer located on human chromosome llp13. Cancer
tamoxifen (Ernster V L. Barclay J. Increases in ductal
Research. 57(5):846-9, 1997). CD44 down-regulation is a 15 carcinoma in situ (DCIS) of the breast in relation to mamprognostic marker for prostate cancer (Noordzij M A van
mography: a dilemma. [Review] [34 refs] Journal of the
Steenbrugge G J. Verkaik NS. Schroder F H. van der Kwast
National Cancer Institute. Monographs. (22): 151-6, 1997;
T H. The prognostic value of CD44 isoforms in prostate
Hwang ES. Esserman LJ. Management of ductal carcinoma
cancer patients treated by radical prostatectomy. Clinical
in situ. [Review] [91 refs] Surgical Clinics of North
Cancer Research. 3(5):805-15, 1997).
20 America. 79(5):1007-30, viii, 1999). These treatment
Human prostate cancer histology is heterogeneous, or
options for DCIS are at best controversial due primarily to
"multi-focal" in nature (Isaacs J T. Bova G S. Prostate
a lack of precision in diagnosis and prognosis of whether the
Cancer. In The Genetic Basis of Human Cancer (Eds.
detected DCIS will progress to invasive breast cancer and
Vogelstein B and Kinzler K W), pp653-60, McGraw-Hill
whether recurrence is likely after treatment, usually with a
Health Professions Division, 1998 and Bova, 1998), with an 25 high percentage being invasive breast cancer (Zaugg K.
average of five lesions in a patient (Bastacky S I. Wojno K
Bodis S. Is there a role for molecular prognostic factors in
J. Walsh P C. Carmichael M J. Epstein J I. Pathological
the clinical management of ductal carcinoma in situ (DCIS)
features of hereditary prostate cancer. Journal of Urology.
of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology.
153(3 Pt 2):987-92, 1995). Between the tumor regions of a
55(2):95-9, 2000). At present, histological grading (nuclear
prostate and within a single tumor region, the genetic causes 30 grading and whether come do-type necrosis is present) and
to the cancer are heterogeneous and independent as well
the size of the DCIS are used to provide assessments of risk
(Sakr WA Macoska J A Benson P. Grignon D J. Wolman
of DCIS to progress into invasive breast cancer (Zaugg K.
S R. Pontes J E. Crissman J D. Allelic loss in locally
Bodis S. Is there a role for molecular prognostic factors in
metastatic, multisampled prostate cancer. Cancer Research.
the clinical management of ductal carcinoma in situ (DCIS)
54(12):3273-7, 1994; Qian J. Bostwick D G. Takahashi S. 35 of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology.
Borell T J. Herath J F. Lieber M M. Jenkins R B. Chromo55(2):95-9, 2000; Shaker B S. Sloane J P. DCIS grading
somal anomalies in prostatic intraepithelial neoplasia and
schemes and clinical implications. [Review] [ 40 refs] Hiscarcinoma detected by fluorescence in situ hybridization.
topathology. 35(5):393-400, 19; van de Vijver M J. Ductal
Cancer Research. 55(22):5408-14, 1995; Mirchandani D.
carcinoma in situ of the breast: histological classification
Zheng J. Miller G J. Ghosh AK. Shibata D K. Cote R J. 40 and genetic alterations. [Review] [ 69 refs] Recent Results in
Roy-Burman P. Heterogeneity in intra tumor distribution of
Cancer Research. 152:123-34, 1998). These parameters are
p53 mutations in human prostate cancer. American Journal
far from being adequate for making the most accurate choice
of Pathology. 147(1):92-101, 1995). In the end, the best
of treatment, resulting in a choice either overly excessive or
predictor of prostate cancer's potential to gain invasiveness
conservative, in either case, the patient will suffer unnecesmay be a consideration of a number of genes whose expres- 45 sarily. Molecular markers can help improve our ability to
sion levels change along the course of cancer development,
better diagnose DCIS and stratify treatment options, espeas demonstrated in principle by Greene et al. (Greene G F.
cially the molecular markers that, themselves, play a role in
Kitadai Y. Pettaway CA von Eschenbach AC. Buucana C
the progression of DCIS to invasive breast cancer (Zaugg K.
D. Fidler I J. Correlation of metastasis-related gene expresBodis S. Is there a role for molecular prognostic factors in
sion with metastatic potential in human prostate carcinoma 50 the clinical management of ductal carcinoma in situ (DCIS)
cells implanted in nude mice using an in situ messenger
of the breast?. [Review] [ 49 refs] Radiotherapy & Oncology.
RNA hybridization technique. American Journal of Pathol55(2):95-9, 2000; Silverstein M J. Masetti R. Hypothesis
ogy. 150(5):1571-82, 1997). Hence, expanding the reperand practice: are there several types of treatment for ductal
tory of such genes, including both the onco-genes and the
carcinoma in situ of the breast?. [Review] [ 53 refs] Recent
suppressor genes, will enhance the accuracy and depend- 55 Results in Cancer Research. 152:105-22, 1998). The tumability of this approach.
origenesis process is a multi-step transformation in which
As for the treatment options of prostate cancer, patients
molecular events escalate to the final stage of invasive
with truly organ-confined prostate cancer can be cured by
phenotype (Silverstein M J. Masetti R. Hypothesis and
radical prostatectomy. Patients with non-organ-confined
practice: are there several types of treatment for ductal
prostate cancers, however, have very low survival rates and 60 carcinoma in situ of the breast?. [Review] [ 53 refs] Recent
the current treatments are largely ineffective (Yagoda A
Results in Cancer Research. 152:105-22, 1998). The conPetrylak D. Cytotoxic chemotherapy for advanced hormoneventional paradigm of protease involvement in the develresistant prostate cancer. [Review] [63 refs] Cancer. 71(3
opment and progression of cancer has been the assignment
Suppl): 1098-109, 1993).
of a usually negative role to the proteases, such as promoting
Breast cancer is the most diagnosed cancer in women and 65 tumor invasion (Mignatti P. Rifkin D B. Biology and biothe second leading cancer related cause of death in women
chemistry of proteinases in tumor invasion. [Review] [306
(Greenlee R T, Murray T, Bolden S, Wingo PA Cancer
refs] Physiological Reviews. 73(1):161-95, 1993). In turn,
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seminal fluid. Purification, tissue distribution, and localizathe conventional paradigm of protease inhibitors in relation
tion in prostate gland. Journal of Biological Chemistry.
to cancer is usually regard of a beneficial effect for the
269(29): 18843-8, 1994; (Yu J X. Chao L. Chao J. Molecupresence of these molecules (Kennedy AR. Chemoprevenlar cloning, tissue-specific expression, and cellular localizative agents: protease inhibitors. Pharmacol Therapeut
78:167-209, 1998). Recently, however, the picture of a new 5 tion of human prostasin mRNA. Journal of Biological
Chemistry. 270(22): 13483-9, 1995). Molecular cloning of
paradigm is beginning to emerge for several serine proteases
a full-length human prostasin cDNA revealed that its prein breast, prostate, and testicular cancers. A "normal epithedicted amino acid residue sequence contains a carboxyllial cell specific-1" (NESl) serine protease was found to be
terminal hydrophobic region that can potentially anchor the
down-regulated in breast and prostate cancers, and it funcprotein on the membrane (Yu J X Chao L. Chao J. Molecular
tions as a tumor suppressor (Goyal J, Smith KM, Cowan J 10
cloning, tissue-specific expression, and cellular localization
M, Wazer D E, Lee SW, Band V. The role for NESl serine
of human prostasin mRNA. Journal of Biological Chemistry.
protease as a novel tumor suppressor. Cancer Res
270(22):13483-9, 1995). At the amino acid level, prostasin
58:4782-4786, 1998). A prostate-specific serine protease,
is similar to plasma kallikrein, coagulation factor XI, hepsin,
prostase (Nelson P S. Gan L. Ferguson C. Moss P. Gelinas
plasminogen, acrosin, prostase, and, in particular, testisin
R. Hood L. Wang K. Molecular cloning and characterization 15 (sharing 44% sequence identity) [Nelson PS. Gan L. Ferof prostase, an androgen-regulated serine protease with
guson C. Moss P. Gelinas R. Hood L. Wang K. Molecular
prostate-restricted expression. Proceedings of the National
cloning and characterization of prostase, an androgenAcademy of Sciences of the United States of America.
regulated serine protease with prostate-restricted expression.
96(6):3114-9, 1999), was shown to be expressed in normal
Proceedings of the National Academy of Sciences of the
prostate but not in prostate cancer cell lines DU-145 and 20 United States of America. 96(6):3114-9, 1999; Hooper JD.
Nicol D L. Dickinson J L. Eyre HJ. Scarman AL. Normy le
PC-3. The expression of a testis-specific serine protease,
J F. Stuttgen MA Douglas M L. Loveland KA Sutherland
testisin, was shown to be lost in testicular cancer through
G R. Antalis T M. Testisin, a new human serine proteinase
either a loss of gene (Hooper JD. Nicol D L. Dickinson J L.
expressed by premeiotic testicular germ cells and lost in
Eyre HJ. ScarmanAL. Normyle J F. Stuttgen MA Douglas
M L. Loveland KA Sutherland G R. Antalis T M. Testisin, 25 testicular germ cell tumors. Cancer Research. 59(13):
3199-205, 1999; Yu J X. Chao L. Chao J. Molecular
a new human serine proteinase expressed by premeiotic
cloning, tissue-specific expression, and cellular localization
testicular germ cells and lost in testicular germ cell tumors.
of human prostasin mRNA. Journal of Biological Chemistry.
Cancer Research. 59(13):3199-205, 1999) or methylation in
270(22):13483-9, 1995). A membrane-bound Xenopus kidthe promoter (Boucaut K, Douglas M, Clements J, Antalis T.
ney epithelial cell sodium channel-activating protease (CAP
The serine proteinase testisin may act as a tumor and/or 30
1) was shown to be highly homologous to human prostasin
growth suppressor in the testis and may be regulated by
as well (sharing 53% sequence identity at the amino acid
DNA methylation. Cancer Genetics and Tumor Suppressor
level) (Vallet V. Chraibi A Gaeggeler H P. Horisberger J D.
Genes, Cold Spring Harbor Laboratory, 2000). Further,
Rossier B C. An epithelial serine protease activates the
transfection of human testicular cancer cells with a testisin
amiloride-sensitive sodium channel. Nature. 389(6651):
cDNAreduced the tumor growth of xenografts of these cells 35 607-10, 1997). Prostasin is encoded by a single-copied
in nude mice, suggesting a tumor suppressor function for
gene, which is located on human chromosome 16pll.2 (Yu
testisin (Boucaut K, Douglas M, Clements J, Antalis T. The
J X. Chao L. Ward D C. Chao J. Structure and chromosomal
serine proteinase testisin may act as a tumor and/or growth
localization of the human prostasin (PRSS8) gene. Genomsuppressor in the testis and may be regulated by DNA
ics. 32(3):334-40, 1996). The secreted prostasin cleaves
methylation. Cancer Genetics and Tumor Suppressor Genes, 40 synthetic substrates in vitro preferentially at the carboxylterminal side of Arg residue, and is thus considered a
Cold Spring Harbor Laboratory, 2000). The testisin serine
trypsin-like serine protease (Yu J X. Chao L. Chao J.
protease is potentially membrane-bound as suggested by its
Prostasin is a novel human serine proteinase from seminal
structure and confirmed by immunohistochemistry gene
fluid. Purification, tissue distribution, and localization in
(Hooper JD. Nicol D L. Dickinson J L. Eyre HJ. Scarman
AL. Normy le J F. Stuttgen MA Douglas ML. Loveland K 45 prostate gland. Journal of Biological Chemistry. 269(29):
18843-8, 1994). The physiological function of prostasin,
A Sutherland G R. Antalis T M. Testisin, a new human
however,
has remained unknown. By comparing gene
serine proteinase expressed by premeiotic testicular germ
expression of normal tissues, pre-invasive cancer, and invacells and lost in testicular germ cell tumors. Cancer
sive cancer, it would be highly advantageous to discover
Research. 59(13):3199-205, 1999.) Prostasin serine promolecular markers that display a differential expression
tease is an acidic protein (pl 4.5-4.8) of approximately 40 50 pattern between the pre-invasive and the invasive phenokDa in molecular mass (Yu J X. Chao L. Chao J. Prostasin
types and use these markers for a more precise diagnosis and
is a novel human serine proteinase from seminal fluid.
prognosis of prostate and/or breast cancers. With the
Purification, tissue distribution, and localization in prostate
enhanced precision in diagnosis and prognosis, treatment
gland. Journal of Biological Chemistry. 269(29):18843-8,
options for patients with DCIS could then be stratified.
1994). It is predominantly made in the prostate gland (-140 55 Those with low risks of developing invasive breast cancer
ng/mg protein), with lesser amounts (2-6 ng/mg protein)
will have a higher confidence in choosing breast-conserving
also found in the bronchi, colon, kidney, liver, lung,
options, while those at high risks will ponder more aggrespancreas, and the salivary glands (Yu J X. Chao L. Chao J.
sive options with the necessary follow-up treatments.
Prostasin is a novel human serine proteinase from seminal
Similarly, those males with low risks of developing invasive
fluid. Purification, tissue distribution, and localization in 60 prostate cancer will have a higher confidence in choosing
prostate gland. Journal of Biological Chemistry. 269(29):
prostate-conserving options, while those at high risks will
18843-8, 1994). Prostasin is secreted in the prostatic fluid,
ponder more aggressive options with the necessary followand can be detected in the semen (-9 µg/ml). Prostasin
up treatments
expression is localized to the epithelial cells of human
SUMMARY OF THE INVENTION
prostate gland by in situ hybridization histochemistry using 65
an antibody or an anti-sense RNA probe (Yu J X. Chao L.
The first objective of the present invention is to reduce
Chao J. Prostasin is a novel human serine proteinase from
deficiencies in the prior art with specific regard to differen-
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tial diagnosis of invasive prostate and breast cancers and to
FIG. 2 is a diagrammatic representation of the analysis of
treatment of invasive and metastatic prostate and breast
prostasin indicative of the absence or existence, or of the
cancers.
invasiveness of human mammary carcinoma.
The second objective of the present invention is to proFIG. 3 shows human prostasin expression in prostate
vide a new marker for prostate and breast cancer.
5 epithelial cells.
The third objective of the invention is to provide as a drug
FIG. 4A shows immunohistochemical detection of prosto patients with carcinoma of the prostate via delivery of a
tasin protein in benign human prostate tissues.
functional prostasin gene.
FIG. 4B is an enlarged view of the boxed region of FIG.
The fourth objective of the invention is to provide as a
drug to patents with carcinoma of the prostate via delivery 10 4A.
of a functional prostasin cDNA.
FIG. 4C shows immunohistochemistry of benign human
prostate tissues with prostasin antibody omitted in the
The fifth objective of the invention is to provide as a drug
procedures, no epithelial cells displayed any staining.
to patents with carcinoma of the breast via delivery of a
functional prostasin gene.
FIG. 4D is an enlarged view of the boxed region of FIG.
The sixth objective of the invention is to provide as a drug 15 4C.
to patents with carcinoma of the breast via delivery of a
FIG. 4E shows immunohistochemistry of human prostate
functional prostasin cDNA.
tumor with prostasin antibody omitted in the procedures, no
This invention identifies prostasin serine protease as a
epithelial cells displayed any staining.
potential marker, and as a tumor invasion suppressor for
FIG. 4F shows immunohistochemical detection of prosprostate and breast cancers and thus provides methods (a), 20 tasin protein in benign human prostate tissue surrounded by
(b), and (c) of determining invasiveness levels of human
prostate carcinomas.
carcmomas:
FIG. 4G shows immunohistochemical detection of pros(a) using prostasin protein levels, comprising the steps of:
tasin protein in Gleason grade 2 prostate tumor.
sampling a human carcinoma tissue; determining prosFIG. 4H is an enlarged view of the boxed region of FIG.
tasin protein levels in the human carcinoma tissue; 25
4G.
preferably by applying an immunological reagentFIG. 4I shows immunohistochemical detection of prostaantibody to said tissue wherein the reagent-antibody
sin protein in Gleason grade 3 prostate tumor.
becomes bound to prostasin protein in said tissue, and
determining invasiveness of the human carcinoma tisFIG. 41 is an enlarged view of the boxed region of FIG.
sue based on the prostasin protein levels:. or
30 41.
(b) using prostasin mRNA levels, comprising the steps of:
FIG. 4K shows immunohistochemical detection of prossampling a human carcinoma tissue; determining prostasin protein in Gleason grade 4 prostate tumor.
tasin mRNA levels in the human carcinoma tissue
FIG. 4L is an enlarged view of the boxed region of FIG.
preferably by applying prostasin-specific anti-sense
4K.
RNA probes in an in situ hybridization to determine the 35
FIG. 5 shows human prostasin expression in human breast
prostasin mRNA levels in the separated human carcicancer cell lines.
noma tissue the determination of the prostasin mRNA
FIG. 6 shows promoter hypermethylation of the human
levels in the separated human carcinoma sample tissue;
prostasin gene in human prostate and breast cancer cell lines.
to make possible and determining invasiveness of the
human carcinoma tissue based on the prostasin mRNA 40
FIG. 7 shows prostasin protein expression and in vitro
levels; or
invasive properties of the DU-145 and the PC-3 transfectants.
(c) (c) using prostasin gene promoter DNA methylation
levels, comprising the steps of: sampling a human
FIG. 8 shows prostasin protein expression and in vitro
carcinoma tissue; determining prostasin gene promoter
invasive properties of the MDA-MB-231 and the MDADNA methylation levels in the human carcinoma 45 MB-435s transfectants.
tissue, preferably by applying prostasin-promoterDESCRIPTION OF THE PREFERRED
specific oligonucleotide primers in a PCR to determine
EMBODIMENT
the prostasin gene promoter DNAmethylation levels in
the sampled human carcinoma tissue and determining
Before explaining the disclosed embodiment of the
invasiveness of the human carcinoma tissue based on 50
present invention in detail it is to be understood that the
the prostasin gene promoter DNA methylation levels,
invention is not limited in its application to the details of the
as well as a method of treating invasive human carcinomas
particular arrangement shown since the invention is capable
comprising the steps of: incorporating human prostasin
of other embodiments. Also, the terminology used herein is
nucleic acid into a selected gene delivery vector nucleic acid
for the purpose of description and not of limitation.
to form a recombinant nucleic acid; preferably wherein the 55
Using RT-PCR and western blot analyses, prostasin pronucleic acid includes a gene or cDNA delivering the recomtein and mRNA expression were found in normal human
binant nucleic acid into a human carcinoma; and reducing
prostate epithelial cells and the human prostate cancer cell
invasiveness of the human carcinoma.
line LNCaP, but discovered not present in the highly invaFurther objects and advantages of this invention will be
sive
human prostate cancer cell lines DU-145 and PC-3.
apparent from the following detailed description of a pres- 60
Immunohistochemistry studies of human prostate cancer
ently preferred embodiment, which is illustrated schematispecimens revealed a down-regulation of prostasin in highcally in the accompanying drawings.
grade tumors.
BRIEF DESCRIPTION OF THE FIGURE
Using RT-PCR and western blot analyses, prostasin proFIG. 1 is a diagrammatic representation of the analysis of 65 tein and mRNA expression were found in a non-invasive
human breast cancer cell line, MCF-7, while invasive human
prostasin indicative of the absence or existence, or of the
breast cancer cell lines MDA-MB-231 and MDA-MB-435s
invasiveness of human prostate carcinoma.
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were also discovered not to express either the prostasin
blot analysis (upper panel), prostasin (as a 40-kDa band) was
detected in normal human prostate epithelial cells (CCprotein or the mRNA. A non-invasive human breast cancer
2555) and the LNCaP cells, but not in the DU-145 or PC-3
cell line, MDA-MB-453, was shown to express prostasin
cells. An equal amount of total protein (100 µg) was loaded
mRNA but not prostasin protein. Examination of the prostasin gene promoter in the human prostate and breast cancer 5 for each sample. At the mRNA level, human prostasin
mRNA (via a 232-bp amplified DNA band) was detected in
cell lines by Southern blot analysis revealed heterogeneous
normal prostate epithelial cells (CC-2555) and the LNCaP
methylation of the promoter in DU-145, PC-3 and MDAcells, but not in the DU145 or PC-3 cells as analyzed by
MB-453 cells, and homogeneous methylation of the proRT-PCR/Southern blot hybridization (middle panel).
moter in MDA-MB-231 and MDA-MB-435s cells. The
prostasin gene promoter in normal human prostate epithelial 10 Co-amplification of a 556-bp human ~-actin message (as
shown in the gel photograph in the lower panel) confirmed
cells, the LNCaP and the prostasin gene promoter in the
the quality and the quantity of the RNA applied in each
human prostate and breast cancer cell lines by Southern blot
RT-PCR.
analysis revealed heterogeneous methylation of the proExpression of prostasin protein is reduced in high-grade
moter in DU-145, PC-3 and MDA-MB-453 cells, and homogeneous methylation of the promoter in MDA-MB-231 and 15 human prostate tumor. Prostatectomy specimens from 39
patients (128 sections) were subjected to immunohistochemMDA-MB-435s cells. The prostasin gene promoter in noristry using a prostasin-specific antibody. Overall, in nonmal human prostate epithelial cells, the LNCaP and the
tumor or benign prostate epithelia, 89.0% of the examined
MCF-7 cells was shown to be unmethylated. Transfection of
areas demonstrated positive staining for prostasin protein
DU-145 and PC-3 cells with a full-length human prostasin
cDNArestored prostasin expression and reduced the in vitro 20 and 11.0% were considered negative (based on the scoring
system used for HercepTest™, DAKO Corporation,
invasiveness by 68% and 42%, respectively. Transfection of
Carpinteria, Calif.). In all tumor specimens that were
MDA-MB-231 and MDA-MB-435s cells with a full-length
examined, prostasin was detected in 93.3% of the low
human prostasin cDNA restored prostasin expression and
Gleason grade areas (~grade 2), 44.4% of Gleason grade 3
reduced the in vitro invasiveness by 50% for either cell line.
Cell proliferation was unaffected by re-expression of pros- 25 areas, 21.1 % of Gleason grade 4 areas, but not in Gleason
grade 5 areas (data summarized in Table 1). The mean
tasin. Our data indicate that prostasin is implicated in normal
prostasin immunostaining score was found significantly
prostate biology and its down-regulation in prostate cancer,
decreased in high-grade prostate tumors as compared to
and its absence in invasive prostate and breast cancer cell
non-tumor areas (ANOVA, p<0.0001).
lines indicates increased invasiveness. Our results also indiRepresentative staining images of non-tumor (benign)
cate that delivering a functional human prostasin gene to 30
areas and prostate tumor areas are shown in FIGS. 4a-4l,
invasive prostate and breast cancers can reduce the invawhich provides immunohistochemical detection of prostasin
s1veness.
protein in tissues. Paraffin-embedded human prostate secFor a facile understanding of the invention embodied
tions were stained for prostasin protein expression evaluaherein, reference should now be made to FIGS. 1and2. FIG.
1 sets forth a schematic for determining if a male has 35 tion using a specific antibody as described (Yu J X. Chao L.
Chao J. Prostasin is a novel human serine proteinase from
prostate cancer. Human blood 10 is taken from the male and
seminal fluid. Purification, tissue distribution, and localizaanalyzed for the presence of prostasin serine protease 14. If
tion in prostate gland. Journal of Biological Chemistry.
NO 12 prostasin is found, there is probably little or no
269(29):18843-8, 1994). Prostasin positive staining (brown
cancer. If there is a presence YES 16 of prostasin serine
40 color) was detected in the cytoplasm and apical membrane
protease 14, there is prostate cancer.
in non-tumor or benign epithelial cells.
If a biopsy of the prostate gland 20 is analyzed for the
The prostasin protein was detected in the cytoplasm and
presence of a normal amount YES 22 of prostasin serine
on
the plasma membrane (apical) of benign epithelial cells
protease 14, there is no cancer or there is non-invasive
lining the secretory lumen as well as in the secretion inside
cancer. If there is NO 24 or Reduced 26 amount of prostasin
45 the lumen (FIGS. 4A and 4B, score 3, or+++), confirming
serine protease 14, there is invasive cancer.
the results of (Yu J X. Chao L. Chao J. Prostasin is a novel
FIG. 2 sets forth a schematic for determining if a female
human serine proteinase from seminal fluid. Purification,
has breast cancer. Human blood 100 is taken from the female
tissue distribution, and localization in prostate gland. Journal
and analyzed for the presence of prostasin serine protease
of Biological Chemistry. 269(29):18843-8, 1994). When a
140. If NO 120 prostasin is found, there is prospectively no 50 pre-immune rabbit serum was used in place of the prostasin
cancer. If there is a presence YES 160 of prostasin serine
antiserum, no staining was observed in either the non-tumor
protease 140, there is breast cancer. If a biopsy of the breast
epithelia (FIGS. 4C and 4D) or tumor epithelia (FIG. 4E).
200 is analyzed for the presence of YES 220 of prostasin
Tumor epithelia displayed various degrees of prostasin
serine protease 140, there is no invasive cancer but may be
immunostaining as shown in FIGS. 4F-4L. In Gleason grade
non-invasive cancer. If there is NO 240 or Reduced 260
55 1-2 tumors, moderate prostasin staining is seen in the
amount of prostasin serine protease 140, there is invasive
cytoplasm and on the plasma membrane of some epithelial
cancer.
cells, as well as in the secretion in the lumen (FIGS. 4G and
The levels of prostasin protein in the epithelial cells of the
4H, score 2, or ++ ). In Gleason grade 3 tumors, a lesser
human prostate gland can be used as a diagnostic marker for
number of epithelial cells displayed the moderate level
the potential invasiveness of prostate tumors. The support- 60 prostasin staining (FIGS. 4I and 41). In Gleason grade 4
ing evidence came from our findings that two invasive
tumors, most epithelial cells did not show any prostasin
human prostate cancer cell lines DU-145 and PC-3 do not
staining, while some prostasin staining can be seen in rare,
express prostasin while normal prostate epithelial cells and
sporadic tumor cells (FIGS. 4K and 4L, as indicated by the
a non-invasive prostate cancer cell line LNCaP express both
arrow, score 0). Genetically, prostate tumors are heterogethe prostasin mRNA and protein
65 neons and multi-focal in nature, in that one patient's grossanatomy tumor comes from multiple initial lesions which
Refer now to FIG. 3 which shows human prostasin
expression in prostate epithelial cells. By means of western
are caused by different initial transformation events and
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progress to different stages by different ensuing transformafragments are generated in the methylation-sensitive
tions (Isaacs J T. Bova GS. Prostate Cancer. In The Genetic
digestion, suggesting incomplete methylation (one of two or
Basis of Human Cancer (Eds. Vogelstein B and Kinzler K
more chromosomes) or clonal methylation in a subW), pp653-60, McGraw-Hill Health Professions Division,
population of cells. For the MDA-MB-231 and MDA-MB1998). The Gleason grading, when used as a percentage of 5 435, however, the Hpa II digestion did not yield the 1,052 bp
each cancer occupied by Gleason grade 4/5 areas, is indebut rather gave the 1,275-bp fragment. This homogeneous
pendently associated with prostate cancer progression
methylation pattern indicates that the Msp I/Hpa II site, at
(Stamey T A, McNeal J E, Yemoto C M, Sigal B M,
location-95 (relative to the transcription initiation site) of the
Johnstone I M. Biological determinants of cancer progresprostasin promoter, is methylated (hypermethylated) in
sion in men with prostate cancer. JAMA 281:1395-1400, 10 these DNA samples. Signal intensity variation may be
1999). We found a significant decrease of prostasin expresattributed to aneuploidy.
sion in the high-grade, i.e., the more progressively transAn examination of the prostasin gene promoter region for
formed tumors.
DNA methylation differences among human prostate and
As earlier indicated, FIG. 5 shows human prostasin
breast cancer cell lines has been made.(see FIG. 6). We
expression in human breast cancer cell lines. By means of 15 found that cells that express prostasin, normal prostate
western blot analysis (upper panel), prostasin (as a 40-kDa
epithelial, LNCaP, and MCF-7, are unmethylated in the
band) was detected in MCF-7 cells, but not in MDA-MBprostasin promoter while MDA-MB-453 showed heteroge453, MDA-MB-231, or MDA-MB-435s cells. An equal
neous prostasin promoter methylation. For cells that do not
amount of total protein (100 µg) was loaded for each sample.
express prostasin, DU-145 and PC-3 showed heterogeneous
At the mRNA level, human prostasin mRNA (via a 232-bp 20 prostasin promoter methylation while MDA-MB-231 and
amplified DNA band) was detected in MCF-7 and MDAMDA-MB-435 showed homogeneous hypermethylation in
MB-453 cells, but not in the MDA-MB-231 or MDA-MBthe promoter region of the prostasin gene.
435s cells as analyzed by RT-PCR/Southern blot hybridizaTwo human prostate cancer cell lines that do not express
tion (lower panel).
prostasin, the highly invasive DU-145 and PC-3, show
Prostasin mRNAexpression is seen absent in two invasive 25
heterogeneous methylation in the promoter region of the
human breast cancer cell lines while two non-invasive breast
prostasin gene. The result suggests that at least one of the
cancer cell lines express prostasin mRNA or protein. Analytwo (or more) chromosome 16's of these cell lines is
sis of prostasin expression in human breast cancer cell lines
methylated at the prostasin gene locus. The prostasin gene
showed that the non-invasive MCF-7 and MDA-MB-453
on the unmethylated chromosome may contain mutations
cells express the prostasin mRNA while the highly invasive 30
that silenced the expression. An alternative explanation for
MDA-MB-231 and MDA-MB-435s cells do not express the
the heterogeneous methylation pattern is that the methylaprostasin mRNA (see FIG. 5). Expression of prostasin
tion occurs in clonal cell populations, however, the lack of
mRNA in normal human breast can be demonstrated by the
detectable prostasin mRNA in our RT-PCR-Southern blot
presence of two GenBank™ normal human breast EST
analysis in the DU-145 and PC-3 cells argues against this
sequences coding for prostasin (Accession numbers 35
possibility.
R48653, and R48557). The MCF-7 cells also express the
The significance of the finding on prostasin gene promoter
prostasin protein as determined by western blot analysis
hypermethylation in prostate or breast cancer is that the
(again see FIG. 5).
measurement of prostasin down-regulation as a cancer
Prostasin down-regulation in prostate or breast cancer can
be caused by promoter methylation or gene-specific muta- 40 marker may be achieved by using a binary assay (yes-or-no),
instead of a gradually decreasing quantity in the immunotion. Prostasin expression decreases with increasing prostate
histochemistry assay (which is quite arbitrary).
cancer grade and is absent in invasive prostate and breast
Re-expression of human prostasin protein in invasive
cancer cell lines. The chromosomal locus where the human
human prostate and breast cancer cells reduces invasiveness
prostasin gene is, 16pll.2, however, is not known to be an
LOH hot-spot in prostate cancer or in breast cancer. Epige- 45 in vitro. At this point, reference should be made to FIG. 7
which shows the prostasin protein expression and in vitro
netic events (such as DNA methylation) may be an alternainvasive properties of the DU-145 and the PC-3 transfective mechanism of loss of expression for tumor suppressors
tants. DU-145 or PC-3 cells transfected with either a vector
or invasion suppressors. Refer now to FIG. 6 which shows
DNA (labeled as "vector") or a prostasin cDNA construct
promoter hypermethylation of the human prostasin gene in
human prostate and breast cancer cell lines. Genomic DNA 50 (labeled as "prostasin") were analyzed by a western blot
analysis using a prostasin-specific antibody (upper panel) or
( 5 µg) from the various cell lines (as indicated in the figure)
subjected to an in vitro Matrigel chemoinvasion assay
were digested with the following restriction enzyme
(lower panel) as described in (Liu D F. Rabbani S A
combinations, Xho I/BamH I(X/B, flanking cuts of the
Induction of urinary plasmiinogen activator by retina acid
methylation-sensitive site), Xho I/BamH I/Msp I (X/B/M),
or Xho l/BamH l/Hpa II (X/B/H). The digests were resolved 55 results in increased invasiveness of human prostate cancer
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed
in a 0.8% agarose gel and transferred to an Immobilon-N
human prostasin protein (a 40-kDa band) was detected in the
membrane for hybridization with a nick-translated prostasin
prostasin cDNA-transfected DU-145 or PC-3 cells, but not
promoter probe (bases 703-1469 of the prostasin gene
in the vector-transfected cells. In the Matrigel chemoinvasequence U33446). The probe detects a promoter fragment
of 1,275 bp, which is cut by the methylation-insensitive 60 sion assay, the vector-transfected cells are expressed as
being 100% invasive (solid bar), the open bar represents the
enzyme Msp I to yield a 1,052-bp fragment for all DNA
relative invasiveness of the human prostasin cDNAsamples. The methylation-sensitive isoschizomer Hpa II
transfected cells. The data were analyzed by a Student t-test
yields the 1,052-bp fragment in the CC-2555 (normal prosusing the Stat view software (Abacus Concepts, Inc.,
tate epithelial cells), the LNCaP, and the MCF-7 samples,
indicating the hypomethylated or unmethylated state of the 65 Berkeley, Calif.).
prostasin promoter in these cells. For DU-145, PC-3, and
It can be seen that Polygonal DU-145 and PC-3 cells
MDA-MB-453 DNA, both the 1,052-bp and the 1,275-bp
transfected with the human prostasin cDNA (designated
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intrinsic limitation that the "positive" identifications are not
DU-145/Pro, and PC-3/Pro, respectively) were confirmed to
express the human prostasin protein, as shown in the western
always confirmed for the "diagnosed" disease. Biopsy is still
blot analysis of the cell lysate (FIG. 7, upper panel). The
required for a true positive identification of prostate cancer
vector-transfected cells, designated DU-145/Vector or PC-3/
even in the case of the application of the PSA prostate cancer
Vector, respectively, were used as negative control in the 5 marker (Catalana W J. Partin AW. Slawin KM. Brawer M
western blot. A further examination of the DU-145/Pro and
K. Flanigan R C. Patel A Richie J P. deKernion J B. Walsh
the PC-3/Pro cells by immunocytochemistry confirmed that
P C. Scardino P T. Lange P H. Subong E N. Parson R E.
100% of the cells expressed the prostasin protein (data not
Gasior G H. Loveland K G. Southwick P C. Use of the
shown). In in vitro Matrigel chemoinvasion assays (FIG. 7,
percentage of free prostate-specific antigen to enhance diflower panel), the invasiveness of DU-145/Pro cells was 10 ferentiation of prostate cancer from benign prostatic disease:
determined to be at 32% of that of DU-145Nector cells (or,
a prospective multicenter clinical trial [see comments].
the reduction of invasiveness was at 68%). The invasiveness
JAMA 279(19):1542-7, 1998). As stated above, it has been
of PC-3/Pro cells was determined to be at 58% of that of
demonstrated in principle that many markers used in a
PC-3Nector cells (or, the reduction of invasiveness was at
multivariate approach may provide a highly accurate diag42%). We performed in vitro cell proliferation assays on 15 nosis (Greene G F. Kitadai Y. Pettaway CA von Eschenbach
DU-145/Pro vs. DU-145Nector cells, and on PC-3/Pro vs.
A C. Bucana C D. Fidler I J. Correlation of metastasisPC-3/Vector cells, but did not observe any difference
related gene expression with metastatic potential in human
between the growth rates of the prostasin cDNA-transfected
prostate carcinoma cells implanted in nude mice using an in
or the vector-transfected cells over an 8-day period (data not
situ messenger RNA hybridization technique. American
shown).
20 Journal of Pathology. 150(5):1571-82, 1997). From the
Forced re-expression of human prostasin in two invasive
standpoint of prostate cancer genetics, the multivariate
human breast cancer cell lines reduced invasiveness. A
approach is well supported by our current understanding. A
full-length human prostasin cDNA under the control of an
serine protease structurally and genetically related to the
RSV promoter was transfected into the invasive breast
PSA, the hK2 (human glandular kallikrein 2) has shown
cancer MDA-MB-231 and MDA-MB-435 cells. Reference 25 some promise of joining the list of markers applicable for
should be made to FIG. 8 which shows prostasin protein
prostate cancer diagnosis (Saedi M S. Hill T M. Kuusexpression and in vitro invasive properties of the MDAReichel K. Kumar A Payne J. Mikolajczyk SD. Wolfert R
MB-231 and the MDA-MB-435s transfectants. MDA-MBL. Rittenhouse H G. The precursor form of the human
231 and MDA-MB-435s cells transfected with either a
kallikrein 2, a kallikrein homologous to prostate-specific
vector DNA (labeled as "vector") or a prostasin cDNA 30 antigen, is present in human sera and is increased in prostate
construct (labeled as "prostasin") were analyzed by a westcancer and benign prostatic hyperplasia. Clinical Chemistry.
ern blot analysis using a prostasin-specific antibody (upper
44(10):2115-9, 1998). Structurally and in prostate gland
panel) or subjected to an in vitro Matrigel chemoinvasion
biology, prostasin shares many common characteristics with
assay (lower panel) as referenced in (Liu D F. Rabbani S A
both PSA and hK2, as being a secreted serine protease made
Induction of urinary plasminogen activator by retina acid 35 in large abundance in prostate epithelial cells (Yu J X. Chao
results in increased invasiveness of human prostate cancer
L. Chao J. Prostasin is a novel human serine proteinase from
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed
seminal fluid. Purification, tissue distribution, and localizahuman prostasin protein (a 40-kDa band) was detected in the
tion in prostate gland. Journal of Biological Chemistry.
prostasin cDNA-transfected MDA-MB-231 and MDA-MB269(29):18843-8, 1994; Yu J X. Chao L. Chao J. Molecular
435s cells, but not in the vector-transfected cells. In the 40 cloning, tissue-specific expression, and cellular localization
Matrigel chemoinvasion assay, the vector-transfected cells
of human prostasin mRNA Journal of Biological Chemistry.
are expressed as being 100% invasive (solid bar), the open
270(22):13483-9, 1995). While high-grade prostate cancer
bar represents the relative invasiveness of the human proscells produce less PSA protein than normal prostate cells or
tasin cDNA-transfected cells. The data were analyzed by a
low-grade prostate cancer cells (Hakalahti L. Vihko P.
Student t-test using the Stat view software (Abacus 45 Henttu P. Autio-Harmainen H. Saini Y. Vihko R. Evaluation
Concepts, Inc., Berkeley, Calif.).
of PAP and PSAgene expression in prostatic hyperplasia and
Stable, polyclonal, episomal transfectants were obtained
prostatic carcinoma using northern-blot analyses, in situ
and the expression of human prostasin protein was conhybridization and immunohistochemical stainings with
firmed by western blot analysis (FIG. 8, upper panel). In in
monoclonal and bispecific antibodies. International Journal
vitro Matrigel chemoinvasion assays, the invasiveness of 50 of Cancer. 55(4):590-7, 1; Sakai H. Yogi Y. Minami Y.
either cell lines expressing human prostasin was reduced by
Yushita Y. Kanetake H. Saito Y. Prostate specific antigen and
50% as compared to the vector-transfected controls (FIG. 8,
prostatic acid phosphatase immunoreactivity as prognostic;
lower panel).
Sakai H. Yogi Y. Minami Y. Yushita Y. Kanetake H. Saito Y.
Taken together, the foregoing evidences linking prostasin
Prostate specific antigen and prostatic acid phosphatase
level reduction or protasin absence to the invasiveness of 55 immunoreactivity as prognostic), the serum PSA levels in
prostate and breast cancer cell lines, or linking prostasin
prostate cancer patients increase due to tissue damage
expression to reduced invasiveness. The evidence qualifies
caused by invasive cancer (Rittenhouse H G. Finlay J A
prostasin as an invasion suppressor, which thus is a marker
Mikolajczyk SD. Partin AW. Human Kallikrein 2 (hK2) and
for diagnosis of invasiveness of prostate and breast cancers,
prostate-specific antigen (PSA): two closely related, but
or as a therapeutic agent to treat invasive prostate and breast 60 distinct, kallikreins in the prostate. [Review] [ 457 refs]
cancers.
Critical Reviews in Clinical Laboratory Sciences. 35(4):
275-368, 1998). By comparison, we also believe prostasin
Pathological grading by the Gleason system is performed
is in the circulation of prostate cancer patients. As a result,
after either surgery or biopsy, both highly invasive
a blood test for the circulating prostasin to indicate the
procedures, while blood tests such as that for the PSA
prostate cancer marker can offer the hope of accurate diag- 65 presence and/or the stage of prostate cancer would be highly
nosis and prognosis without the harm of an invasive proceuseful. (as illustrated in FIG. 1). In principal, the feasibility
of a blood test based on prostasin detection to indicate
dure. In practice, however, single markers suffer from an
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cancer has been demonstrated by Berteau et al. (1999).
These authors (Berteau P. Laribi Eschwege P. Lebars I.
Dumas F. Benoit G. Lorie S. Prostasin mRNA to detect
prostate cells in blood of cancer patients. Clinical and
Chemical Laboratory Medicine 37 (SS): S119, 1999), demonstrated a highly promising potential of using prostasin as
a marker to detect circulating prostate epithelial cells, a sign
of prostate tissue damage caused by invasive prostate cancer
leading to the dissemination of prostate epithelial cells into
the circulation. It is expected that a blood test for circulating
prostasin to indicate the presence and/or the stage of breast
cancer would be highly useful. (as illustrated in FIG. 2).
In summary of the invention, it has been taught herein
that: protein prostasin as well as its MRA levels and its gene
promoter DNA methylation levels can be used to determine
the invasiveness level of human carcinomas; and, provide a
method of treating invasive human carcinomas by delivery
thereto of a recombinant nucleic acid formed by a human
prostasin nucleic acid incorporated into a selected gene
delivery vector. Those teachings are repeated for emphasis
in the following:
1. Immunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin
in high-grade tumors.
2. Using RT-PCR and western blot analyses, prostasin
protein and mRNA expression were found in a noninvasive human breast cancer cell line, MCF-7, while
invasive human breast cancer cell lines MDA-MB-231
and MDA-MB-435s were found not to express either
the prostasin protein or the mRNA. A non-invasive
human breast cancer cell line, MDA-MB-453, was
shown to express prostasin mRNA but not prostasin
protein: and,
3. Examination of the prostasin gene promoter in the
human prostate and breast cancer cell lines by Southern
blot analysis revealed heterogeneous methylation of the
promoter in DU-145, PC-3 and MDA-MB-453 cells,
and homogeneous methylation of the promoter in
MDA-MB-231 and MDA-MB-435s cells. The prostasin gene promoter in normal human prostate epithelial
cells, the LNCaP and the MCF-7 cells was shown to be
unmethylated. Transfection of DU-145 and PC-3 cells
with a full-length human prostasin cDNA restored
prostasin expression and reduced the in vitro invasiveness by 68% and 42%, respectively. Transfection of
MDA-MB-231 and MDA-MB-435s cells with a fulllength human prostasin cDNA restored prostasin
expression and reduced the in vitro invasiveness by
50% for either cell line.
The preferred methods of separating sampled human
carcinoma tissue from neighboring normal tissues is by laser
capture micro-dissection.

18
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
5 deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
We claim:
10
1. A method of determining human prostate carcinomas
non-invasiveness using prostasin gene promoter DNA
methylation levels, comprising the steps of:
15

20

25

30

35

40

45

50

sampling a human prostate carcinoma tissue;
determining prostasin gene promoter DNA methylation
levels in the human carcinoma tissue; and
determining the human prostate cancer is not invasive
based on the lack of DNA methylation of the prostasin
gene promoter.
2. The method of claim 1, wherein the step of determining
gene promoter DNA methylation levels includes:
applying prostasin-promoter-specific DNA probes in a
southern blot hybridization analysis to determine the
prostasin gene promoter DNAmethylation levels in the
sampled human prostate carcinoma tissue.
3. The method of claim 1, wherein the sampling comprises:
separating the human carcinoma tissue from the neighboring normal tissue by laser capture micro-dissection.
4. A method of determining human breast carcinomas
non-invasiveness using prostasin gene promoter DNA
methylation levels, comprising the steps of:
sampling a human breast tissue;
determining prostasin gene promoter DNA methylation
levels in the human carcinoma tissue; and
determining the human prostate cancer is not invasive
based on the lack of DNA methylation of the prostasin
gene promoter.
5. The method of claim 4, wherein the step of determining
gene promoter DNA methylation levels includes:
applying prostasin-promoter-specific DNA probes in a
southern blot hybridization analysis to determine the
prostasin gene promoter DNAmethylation levels in the
sampled human breast carcinoma tissue.
6. The method of claim 4, wherein the sampling comprises:
separating the human carcinoma tissue from the neighboring normal tissue by laser capture micro-dissection.
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